Non-melanoma skin cancers pose substantial recurrence risk and health care burden. Delayed diagnosis increases tissue destruction, functional loss, and costs. Adherence to evidence-based clinical practice guidelines improve risk stratification, surveillance, and outcomes across patient populations.
Today, we have a rundown of seven of the most recent clinical guidelines and a consensus statement from leading medical societies including the Society for Immunotherapy of Cancer (SITC), the British Association of Dermatologists (BAD), and more.
Non-Melanoma Skin Cancer Clinical Guidance
- Management of Basal Cell Carcinoma in Gorlin Syndrome
- Consensus and Physician Experts (CPE), October 2025
- Management of People with Cutaneous Squamous Cell Carcinoma in situ (Bowen Disease)
- British Association of Dermatologists (BAD), February 2023
- Immunotherapy for the Treatment of Nonmelanoma Skin Cancer
- Society for Immunotherapy of Cancer (SITC), July 2022
- Management of People with Cutaneous Squamous Cell Carcinoma
- British Association of Dermatologists (BAD), March 2021
- Management of Adults with Basal Cell Carcinoma
- British Association of Dermatologists (BAD), November 2021
- Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin
- American Society for Radiation Oncology (ASTRO), February 2020
- Management of Basal Cell Carcinoma
- American Academy of Dermatology (AAD), March 2018
Check out other clinical guidelines and sign up for alerts to stay informed on the latest published guidelines and insights.
Copyright © 2026 Guideline Central, all rights reserved.